Well, first of all, the IEA uh thinks the exact opposite of that. The Israelis think the opposite of it. Our CIA thinks the opposite.So, it's just preposterous. Uh the Israelis did plenty of damage before we came in. And uh when we came in, it added um it it it basically created lots of certainty around eradication of their ability to weaponize and to enrich.There are three nuclear reactors uh at play here. Two are in the tons, one above ground, one below ground. Then the Ford do nuclear reactor which every ...

Well, joining us now is CrowdStrike CEO George Kurtz. Crowd Strike is up 42% so far this year. George, it's great to have you back on the show.Welcome. Great to be here. Thank you.So, I'm going to start right there with you. Um, how acute is the risk of cyber security incidents from Iran in the wake of everything we've seen right now. Well, what's important to realize is whenever geopolitical tensions rise, you're going to see a natural increase in cyber attacks.And that's exactly what we've seen. Iran has ...

Vafseo Launch and Market Opportunity - Vafseo (vadadustat) has launched as a treatment for anemia due to chronic kidney disease (CKD) in adult patients on dialysis[8] - The U S market opportunity for Vafseo in the dialysis patient population is approximately $1 billion[8] - Akebia is pursuing label expansion of Vafseo for the late-stage non-dialysis CKD population, representing a multi-billion-dollar U S market opportunity[8] - Contracts are secured covering nearly 100% of U S dialysis patients for Vafseo[12, 20] Clinical and Patient Considerations - Current standard of care for dialysis patients (ESAs) has remained unchanged for 30 years, with nearly 25% of patients falling below target hemoglobin levels[13] - Approximately 20% of patients on dialysis are ESA hyporesponders, leading to higher hospitalization and mortality rates[13] - Market research indicates that over 2 out of 3 nephrologists identify an unmet need for anemia treatment in CKD, particularly for oral options and ESA-resistant patients[14] VOICE Trial and Label Expansion - The VOICE trial, with over 650 subjects enrolled as of January 10, 2025, is designed to demonstrate non-inferiority for all-cause mortality and superiority for a 10% reduction in all-cause hospitalization[23, 24] - A Phase 3 clinical trial for Vafseo in late-stage CKD patients not on dialysis is planned to begin in mid-2025[8, 46] Non-Dialysis Market - In patients with pre-hemodialysis Hb <9 0 g/dL (n=4855), 73 4% did not receive ESA pre-HD[26] - The U S non-dialysis market opportunity for anemia treatment is approximately $1 billion, driven by predominantly private and unbundled government payment structures[40, 41] HIF-based Pipeline - Akebia is advancing a HIF-based pipeline targeting high unmet needs, including ROP (rare disease) with a ~$1 5B+ U S market opportunity and ~30K patients[50]

Vafseo Launch and Market Opportunity - Vafseo (vadadustat) has launched as a treatment for anemia due to chronic kidney disease (CKD) in adult patients on dialysis[8] - The U S market opportunity for Vafseo in the dialysis patient population is approximately $1 billion[8] - Akebia is pursuing label expansion of Vafseo for the late-stage non-dialysis CKD population, representing a multi-billion-dollar U S market opportunity[8] - Contracts are secured covering nearly 100% of U S dialysis patients for Vafseo[12, 20] Clinical and Patient Considerations - Current standard of care for dialysis patients (ESAs) has remained unchanged for 30 years, with nearly 25% of patients falling below target hemoglobin levels[13] - Approximately 20% of patients on dialysis are ESA hyporesponders, leading to higher hospitalization and mortality rates[13] - Market research indicates that over 2 out of 3 nephrologists identify an unmet need for anemia treatment in CKD, particularly for oral options and ESA-resistant patients[14] Vafseo Advantages and Ongoing Trials - Vafseo is an oral HIF-PH inhibitor with the potential to become standard of care, offering a unique mechanism of action and convenient oral dosing[15] - The VOICE trial, with a target enrollment of ~2,200 patients, is underway to demonstrate Vafseo's non-inferiority for all-cause mortality and superiority for a 10% reduction in all-cause hospitalization[24] Non-Dialysis Market and Future Plans - In patients with pre-hemodialysis Hb <9 0 g/dL (n=4855), 73 4% did not receive ESA pre-HD[26] - A Phase 3 clinical trial is planned to begin in mid-2025 for Vafseo in patients with late-stage CKD anemia not on dialysis, targeting ~1,500 U S subjects[8, 46] Pipeline and Financial Outlook - Akebia expects its existing cash resources and cash from operations to be sufficient to fund its current operating plan for at least two years[8] - Akebia is advancing a HIF-based pipeline targeting high unmet needs, including ROP (~$1 5B+ U S market opportunity), ARDS (~$2B U S market opportunity), and CS associated AKI (~$1 5B+ U S market opportunity)[50]

For the exclusive use of JATIN CHAWLA at TVF CAPITAL ADVISORS PTE LTD on 22-Jun-2025 22 June 2025 Global Semiconductor Capital Equipment China WFE Import Tracker (May 2025): Imports resilient with YTD YoY -2%, upside risk to our full year projection Qingyuan Lin, Ph.D. +852 2123 2654 qingyuan.lin@bernsteinsg.com Stacy A. Rasgon, Ph.D. +1 213 559 5917 stacy.rasgon@bernsteinsg.com David Dai, CFA +852 2918 5704 david.dai@bernsteinsg.com Zheng Cui +852 2123 2694 zheng.cui@bernsteinsg.com Alrick Shaw +1 917 344 ...

Core Viewpoint - Costco Wholesale is experiencing a mixed investment outlook with both bullish and bearish signals affecting its stock performance [2] Group 1: Bullish Factors - Strong fiscal Q3 2025 earnings report showed revenue of $63.21 billion, an 8% year-over-year increase, and net income rose 13% despite a one-time $130 million accounting charge [4][6] - Membership retention remains robust with a global renewal rate of 90.2%, and 73% of membership sales are from the premium Executive card, contributing to over 10% growth in quarterly membership income [6][7] - The company maintains a solid financial position with a debt-to-equity ratio of 0.21 and a quick ratio of 1.02, alongside an increase in cash flow from operating activities to $11.34 billion in 2024 [7] Group 2: Bearish Factors - Costco's current P/E ratio of 56.82 is significantly higher than the market average of 23.70 and the retail sector average of 28.34, raising concerns about valuation [9] - Future earnings growth is projected at only 9% over the next 12 months, which may not justify the high valuation [10] - E-commerce growth has slowed from 40% year-over-year to 15% in Q3 2025, potentially impacting overall sales as consumer confidence wanes [14] Group 3: Stock Forecast - The 12-month stock price forecast for Costco is $1,034.79, indicating a potential upside of 3.28% from the current price of $1,001.92 [15] - Analysts suggest that while Costco has a Moderate Buy rating, caution is advised due to current market conditions and technical indicators [18]

Target is reportedly testing a service that would ship products directly from factories to customers’ homes.By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions .Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.The service would focus on low-cost products like apparel, ...

Here to break down the chart in crude is Renaissance Macros's Jeff Degraphth. It's good to see you. Welcome back.Thanks, Scott. I mean, a remarkable trade when you consider what people were worried about and then in a couple of days how the reversal has taken place. It's pretty stunning.Yeah, it certainly is. Um, look, you had an overbought condition. Um, that overbought condition was driven by obviously fear and sentiment, but that was taking place in the whole context of a downtrend. And that downtrend's ...

you. We're joined now by Schwab's chief investment strategist, Liz Anne Saunders. It's good to see you.Um, we're not that far away from new highs and you can thank the growth factor for getting us there, can't you. Yeah. So, that's been interesting.Momentum has certainly picked up as a factor doing well and that's not surprising when you get these kind of rip higher rallies. But aside from that, which isn't really a fundamental factor, it's more like a concept. It just means that stocks that have been worki ...

I specialize in constructing investment portfolios aimed at generating additional income through dividends. My focus lies on identifying companies with significant competitive advantages and strong financials that can provide you with an attractive Dividend Yield and Dividend Growth, thus enabling you to augment your dividend income annually. By combining high Dividend Yield and Dividend Growth companies, you can gradually reduce your dependence on the broader stock market fluctuations.I also assist you in ...